Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. Issue 8 (16th August 2018)

• Record Type: Journal Article
• Authors: Rossi, Cédric; Gilhodes, Julia; Maerevoet, Marie; Herbaux, Charles; Morschhauser, Franck; Brice, Pauline; Garciaz, Sylvain; Borel, Cécile; Ysebaert, Loïc; Obéric, Lucie; Lazarovici, Julien; Deau, Bénédicte; Dupuis, Jehan; Chauchet, Adrien; Abraham, Julie; Bijou, Fontanet; Stamatoullas‐Bastard, Aspasia; Malfuson, Jean‐Valère; Golfier, Camille; Laurent, Camille; Pericart, Sarah; Traverse‐Glehen, Alexandra; Kanoun, Salim; Filleron, Thomas; Casasnovas, René‐Olivier; Ghesquières, Hervé
• Is Part Of: American journal of hematology. Volume 93:Issue 8(2018:Aug.)
• Page Start: 1042
• Page End: 1049
• Publication Date: 2018-08-16
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.25154
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti‐PD‐1 is not well known. We retrospectively investigated the efficacy of salvage therapies for unsatisfactory response to anti‐PD‐1 therapy, assessed by PET‐CT according to the Lugano criteria, in 30 R/R HL patients. Patients were highly pretreated before anti‐PD‐1 (70% received ASCT and 93% BV). Unsatisfactory responses to anti‐PD1 therapy were progressive disease (PD) ( n = 24) and partial response (PR) ( n = 6). For the 24 PD patients, median anti‐PD‐1 related PFS was 7.5 months (95%CI, 5.7‐11.6); 17 received subsequent CT alone (Group 1) and 7 received CT in addition to anti‐PD‐1 (Group 2). 16/24 patients (67%) obtained an objective response. In the 15 patients treated with the same CT, twelve obtained PR or complete response (CR). In Group 1, there were 7 CR (41%), 3 PR (18%), and 7 PD (41%). In Group 2, there were 4 CR (57%), 2 PR (29%), and 1 SD (14%). No unexpected toxicity was observed. Six patients who achieved response proceeded to allogeneic SCT. With a median follow‐up of 12.1 months (7‐14.7), the median PFS following the initiation of CT was 11 months (95% CI 6.3‐not reached) and the median of overall survival was not reached. These observations in highly pretreated HL patients suggest that anti‐PD‐1 therapy might re‐sensitize tumor cells to CT.